Role of remote sensing, geographic bioinformatics system and bioinformatics in kala-azar epidemiology

Bhunia, Gouri Sankar; Dikhit, Manas Ranjan; Kesari, Shreekant; Sahoo, Ganesh Chandra; Das, Pradeep
November 2011
Journal of Biomedical Research;Nov2011, Vol. 25 Issue 6, p373
Academic Journal
Abstract: Visceral leishmaniasis or kala-azar is a potent parasitic infection causing death of thousands of people each year. Medicinal compounds currently available for the treatment of kala-azar have serious side effects and de-creased efficacy owing to the emergence of resistant strains. The type of immune reaction is also to be considered in patients infected with Leishmania donovani (L. donovani). For complete eradication of this disease, a high level modern research is currently being applied both at the molecular level as well as at the field level. The computa–tional approaches like remote sensing, geographic information system (GIS) and bioinformatics are the key re-sources for the detection and distribution of vectors, patterns, ecological and environmental factors and genomic and proteomic analysis. Novel approaches like GIS and bioinformatics have been more appropriately utilized in determining the cause of visearal leishmaniasis and in designing strategies for preventing the disease from spread–ing from one region to another.


Related Articles

  • Amphotericin-b-liposomal.  // Reactions Weekly;Aug2014, Vol. 1516 Issue 1, p26 

    An abstract of the article "Reversible ototoxicity: A rare adverse reaction of liposomal amphotericin-B used for the treatment of antimony-resistant visceral leishmaniasis in an elderly male," by P. C. Das and colleagues is presented.

  • Miltefosine/sodium stibogluconate.  // Reactions Weekly;11/24/2007, Issue 1179, p24 

    The article describes the case of four patients who, while receiving sodium stibogluconate or miltefosine for visceral leishmaniasis, developed thrombocytopenia. IM sodium stibogluconate 4mL morning and evening for 8 days was given to a 28-year-old woman. She had a fever of 100°F when she was...

  • Treatment of Visceral Leishmaniasis. Moore, E. M.; Lockwood, D. N. // Journal of Global Infectious Diseases;May2010, Vol. 2 Issue 2, p151 

    The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, adverse effects and cost, making treatment a complex issue. We review the evidence relating to the different methods of treatment in relation to - efficacy and toxicity of the drugs in different...

  • One-Year Follow-up of Immunocompetent Male Patients Treated With Miltefosine For Primary Visceral Leishmaniasis in Bihar, India. Burza, Sakib; Nabi, Emara; Mahajan, Raman; Mitra, Gaurab; Lima, María Angeles // Clinical Infectious Diseases;Nov2013, Vol. 57 Issue 9, p1363 

    A letter to the editor is presented in response to the article "Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use" by S. Sundar and colleagues in a 2012 issue of the journal.

  • Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent. Meheus, Filip; Balasegaram, Manica; Olliaro, Piero; Sundar, Shyam; Rijal, Suman; Faiz, Md. Abul; Boelaert, Marleen // PLoS Neglected Tropical Diseases;Sep2010, Vol. 4 Issue 9, p1 

    Background: Visceral leishmaniasis is a systemic parasitic disease that is fatal unless treated. We assessed the cost and costeffectiveness of alternative strategies for the treatment of visceral leishmaniasis in the Indian subcontinent. In particular we examined whether combination therapies...

  • Of Cattle, Sand Flies and Men: A Systematic Review of Risk Factor Analyses for South Asian Visceral Leishmaniasis and Implications for Elimination. Bern, Caryn; Courtenay, Orin; Alvar, Jorge // PLoS Neglected Tropical Diseases;Feb2010, Vol. 4 Issue 2, p1 

    Background: Studies performed over the past decade have identified fairly consistent epidemiological patterns of risk factors for visceral leishmaniasis (VL) in the Indian subcontinent. Methods and Principal Findings: To inform the current regional VL elimination effort and identify key gaps in...

  • Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial. Hailu, Asrat; Musa, Ahmed; Wasunna, Monique; Balasegaram, Manica; Yifru, Sisay; Mengistu, Getahun; Hurissa, Zewdu; Hailu, Workagegnehu; Weldegebreal, Teklu; Tesfaye, Samson; Makonnen, Eyasu; Khalil, Eltahir; Ahmed, Osama; Fadlalla, Ahmed; El-Hassan, Ahmed; Raheem, Muzamil; Mueller, Marius; Koummuki, Yousif; Rashid, Juma; Mbui, Jane // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is increasing. Improved treatment options are needed. Paromomycin was shown to be an efficacious...

  • Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study. Musa, Ahmed M.; Younis, Brima; Fadlalla, Ahmed; Royce, Catherine; Balasegaram, Manica; Wasunna, Monique; Hailu, Asrat; Edwards, Tansy; Omollo, Raymond; Mudawi, Mahmoud; Kokwaro, Gilbert; El-Hassan, Ahmed; Khalil, Eltahir // PLoS Clinical Trials;Oct2010, Vol. 7 Issue 10, Special section p1 

    Background: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan.We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15...

  • Miltefosine Effectively Modulates the Cytokine Milieu in Indian Post Kala-Azar Dermal Leishmaniasis. Mukhopadhyay, Debanjan; Kanti Das, Nilay; Roy, Susmita; Kundu, Sunanda; Barbhuiya, J. N.; Chatterjee, Mitali // Journal of Infectious Diseases;11/1/2011, Vol. 204 Issue 9, p1427 

    Background. The increasing incidence of unresponsiveness to antimonials in leishmaniasis prompted the use of newer drugs such as miltefosine. Miltefosine influences macrophage effector functions, but its effect on patients with post kala-azar dermal leishmaniasis (PKDL) has not been evaluated....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics